NCT04526509 - Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

June 8, 2023

Study Completion Date

June 8, 2023

Conditions

Neoplasms

Interventions

DRUG

GSK3901961

GSK3901961 as an IV infusion.

DRUG

GSK3845097

GSK3845097 as an IV infusion.

DRUG

GSK4427296

GSK4427296 as an IV infusion.

DRUG

Cyclophosphamide

Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

DRUG

Fludarabine

Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

Trial Locations (17)

3000

GSK Investigational Site, Melbourne

10032

GSK Investigational Site, New York

10065

GSK Investigational Site, New York

21287

GSK Investigational Site, Baltimore

30322

GSK Investigational Site, Atlanta

32224

GSK Investigational Site, Jacksonville

40536

GSK Investigational Site, Lexington

50937

GSK Investigational Site, Cologne

63110

GSK Investigational Site, St Louis

66205

GSK Investigational Site, Westwood

77030

GSK Investigational Site, Houston

81377

GSK Investigational Site, Munich

M5G 2M9

GSK Investigational Site, Toronto

H1T 2M4

GSK Investigational Site, Montreal

01307

GSK Investigational Site, Dresden

1066 CX

GSK Investigational Site, Amsterdam

SE-171 64

GSK Investigational Site, Stockholm